Almirall marked World Psoriasis Day by drawing attention to the need to keep improving how patients are cared for and to move dermatology services toward more innovative, personalised ways of working, El Diario Vasco reports. The company, which specialises in medical dermatology, says its approach pairs its own research investment with close cooperation with healthcare professionals and hospital pharmacy staff.
According to El Diario Vasco, the Barcelona-based firm used the awareness day to argue that better care depends as much on how services are organised as on the treatments themselves.
Why it matters
Psoriasis is a long-term skin condition that requires ongoing management rather than a single course of treatment, which makes the way care is delivered over time central to patient outcomes. El Diario Vasco reports that Almirall sees room to improve that delivery through innovation and a more tailored approach in dermatology.
The company's message places hospital pharmacy at the centre of the effort. In its account, hospital pharmacists are pivotal in turning research advances into everyday clinical practice — a link between what is developed and what patients actually receive.
That framing matters because it shifts attention from the laboratory to the clinic. New options only help patients if the systems around them — prescribing, dispensing, follow-up and monitoring — are set up to deliver them consistently.
Hospital pharmacy as the bridge to practice
El Diario Vasco reports that Almirall describes hospital pharmacy as playing a key part in bringing innovation into routine care. The company's stated model combines investment in research with collaboration with health professionals and hospital pharmacy services.
In practical terms, that means the path from a promising development to a patient's treatment runs through pharmacy teams who handle hospital-based medicines and support their safe use. Almirall's emphasis on this partnership suggests it views the pharmacy role as more than logistical.
The company also points to improving care processes as a goal in its own right, alongside the treatments themselves. El Diario Vasco reports that, in Almirall's view, refining these processes and the potential offered by tools such as artificial intelligence could open new ways to monitor patients, including those with psoriasis.
AI and the monitoring question
The mention of artificial intelligence is framed as a possibility rather than a finished solution. According to El Diario Vasco, Almirall sees AI as one of several avenues that could support patient follow-up in dermatology, without offering specifics on how such tools would be used or when they might reach clinics.
For a condition managed over the long term, monitoring is a recurring challenge. Regular assessment helps clinicians judge whether a treatment is working and adjust it when it is not. Any technology that makes that tracking more consistent could, in principle, ease pressure on both patients and specialists — though Almirall's comments as reported do not go beyond identifying the potential.
The company's broader argument is that technology alone is not enough. El Diario Vasco reports that Almirall also stresses the need to bring scientific knowledge closer to day-to-day practice and to make care increasingly personalised.
Three routes to better services
Taken together, the company's position sets out three connected routes to improving dermatology care: research, new tools and personalised attention. El Diario Vasco reports that Almirall presents these as complementary paths rather than alternatives.
Research supplies the treatments. Tools, including the possible use of AI, could sharpen how patients are tracked. Personalised attention addresses the fact that psoriasis affects individuals differently and that a single standard approach may not suit everyone.
The company's World Psoriasis Day messaging does not include new clinical data, product announcements or timelines. Instead, it is a statement of direction from a dermatology-focused drugmaker about how it believes care should evolve — and about the partners it intends to work with along the way.
El Diario Vasco's report frames the occasion as a moment for the company to restate its commitment to patients and to the health professionals and hospital pharmacy staff who deliver their care.
What to watch is whether the emphasis on AI-assisted monitoring and redesigned care processes moves from stated ambition into concrete programmes, and how hospital pharmacy's role develops as those efforts take shape.
